High Quality Men Health Mucuna Pruriens Extract Levo-Dopa

• Certification: ISO
• Assay Method: HPLC
• Application Form: Tablet, Capsule
• Application: Food
• State: Powder
• Extract Source: Mucuna Pruriens
• Model NO.: 20%-98% Levo-Dopa
• Botanical Source: Mucuna Pruriens
• Plant Part Used: Seed, 100% Natural
• Appearance: Fine off White Powder
• Ratio: 10:1
• Loss on Drying: Nmt 5.0%
• Ash Content: Nmt 5.0%
• Heavy Metals: Nmt 10ppm
• Arsenic (as): Nmt 2ppm
• Lead (Pb): Nmt 3ppm
• Cadmium (CD): Nmt 1ppm
• Mercury(Hg): Nmt 0.5ppm
• Total Plate Count: < 10,000cfu/G
• Mold & Yeast: < 1000cfu/G
• E.Coli: Negative
• Staphylococcus: Negative
• Transport Package: Packed in Fiber Drum, LDPE Bag Inside; 25kg
• Specification: 20%-98% Levo-Dopa
• Trademark: Kingherbs
• Origin: Yongzhou of Hunan Province
• HS Code: 2938909090
• Production Capacity: 500000 Ton/Year

Product Description

Mucuna Pruriens Seed Extract                     

Mucuna Pruriens Seed Extract
Latin Name: Mucuna pruriens(linn.)
Part Used:Seed
CAS#:59-92-7
Specification:
20%  Levo-Dopa
99%  Levo-Dopa   BP2007
4:1   Mucuna Pruriens Seed Extract
 

Analysis Items		Specifications
Appearance		Fine off White Powder
Odor & Taste		Characteristic
Bulk Density		45-55g/100ml
Mesh Size		NLT 98% through 80 Mesh
Assay		NLT 20% L-dopa
Loss on Drying		NMT 5.0%
Ash		NMT 5.0%

 
L-DOPA crosses the protective blood-brain barrier, whereas dopamine itself cannot. Thus, L-DOPA is used to increase dopamine concentrations in the treatment of Parkinson's disease and dopamine-responsive dystonia. This treatment was made practical and proven clinically by George Cotzias and his coworkers, for which they won the 1969 Lasker Prize.Once L-DOPA has entered the central nervous system, it is converted into dopamine by the enzyme aromatic L-amino acid decarboxylase, also known as DOPA decarboxylase.  Pyridoxal phosphate (vitamin B6) is a required cofactor in this reaction, and may occasionally be administered along with L-DOPA, usually in the form of pyridoxine.
Besides the central nervous system, L-DOPA is also converted into dopamine from within the peripheral nervous system. Excessive peripheral dopamine signaling causes many of the adverse side effects seen with sole L-DOPA administration. To bypass these effects, it is standard clinical practice to coadminister (with L-DOPA) a peripheral DOPA decarboxylase inhibitor (DDCI) such as carbidopa (medicines containing carbidopa, either alone or in combination with L-DOPA, are branded as Lodosyn(Aton Pharma) Sinemet (Merck Sharp & Dohme Limited), Pharmacopa (Jazz Pharmaceuticals), Atamet (UCB), and Stalevo (Orion Corporation) or with a benserazide (combination medicines are branded Madopar or Prolopa),to prevent the peripheral synthesis of dopamine from L-DOPA. Coadministration of  pyridoxine without a DDCI accelerates the peripheral decarboxylation of L-DOPA to such an extent that it negates the effects of L-DOPA administration, a phenomenon that historically caused great confusion.
In addition, L-DOPA, co-administered with a peripheral DDCI, has been investigated as a potential treatment for restless leg syndrome. However, studies have demonstrated "no clear picture of reduced symptoms".
The two types of response seen with administration of L-DOPA are: